City/Town where Organization Located
New Haven, CT
Company/organization description (<500 characters)
Cybrexa is a privately-held biotechnology company dedicated to developing next-generation tumor-targeted cancer therapies using its alphalex™ platform. The Company’s lead candidate, CBX-12, an alphalex™-exatecan conjugate, is expected to enter Phase I in 2021 in advanced solid tumors. Cybrexa also has other preclinical toxin conjugate programs as well as synthetic lethality programs. Cybrexa was founded by physician-scientists and has an experienced management team that has built numerous successful life sciences companies.
Tell us about the milestones your venture accomplished in 2019, eg., key team members added, revenue level achieved, major sales made or endorsements received, successful exit, etc... (<500 characters)
In 2019, we expanded our pipeline to four programs and selected a lead candidate, CBX-12, with high potential in solid tumors. Also, we expanded our chemistry and biology labs at 5 Science Park in New Haven and hired additional PhD scientists to progress our programs. Finally, we closed a $13.4M round of financing, bringing the total funds Cybrexa has raised to $31M.
Stage: Does your venture generate revenue? YES or NO
What CT entrepreneur ecosystem resources (spaces, programs, events, schools, etc.) have helped you succeed? (<500 characters)
Organizations like Connecticut Innovations, CTNext, and BioCT have been critical in providing financing and a network to grow our company in New Haven. Yale University and the Office of Cooperative Research have been instrumental in providing technology and expertise to advance our programs. Also, the amazing scientific talent in Connecticut has enabled our success - and to grow from a startup to a biotech on the cusp of entering the clinic with our first antitumor therapy in just three years
What people are saying about Cybrexa...
Cybrexa is a privately-held biotechnology company dedicated to developing an entirely new class of cancer therapies using its alphalex™ platform to deliver anti-cancer agents directly into tumor cells. The Company’s lead candidate, CBX-11, an alphalex™-PARP inhibitor combination, is in preclinical development with advancing plans to initiate clinical development. Cybrexa was founded by physician-scientists, and has an experienced management team that has built numerous successful life sciences companies and raised hundreds of millions of dollars in venture capital. For more information about Cybrexa, please visit www.cybrexa.com. Bill Kenney